Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Prevnar 13

Known as: PCV-13 vaccine, prevenar 13, PCV13 vaccine 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

13-valent pneumococcal vaccinePneumococcal 13-valent conjugate vaccine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage.
BACKGROUND We studied the impact of 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of invasive pneumococcal… Expand
2016
2016
Epidemiology of Invasive Pneumococcal Disease in Bangladeshi Children Before Introduction of Pneumococcal Conjugate Vaccine
Background: Because Bangladesh intended to introduce pneumococcal conjugate vaccine (PCV)-10 in 2015, we examined the baseline… Expand
2015
2015
Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine.
OBJECTIVES To describe the distribution of vaccine and non-vaccine pneumococcal serotypes from adult patients for different… Expand
  • table 1
  • figure 1
  • table 4
  • table 2
  • table 3
Highly Cited
2014
Highly Cited
2014
Invasive Pneumococcal Disease After Implementation of 13-Valent Conjugate Vaccine
OBJECTIVE: To examine whether there is a different clinical profile and severity of invasive pneumococcal disease (IPD) in… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Highly Cited
2014
Highly Cited
2014
Direct and Indirect Effects of PCV13 on Nasopharyngeal Carriage of PCV13 Unique Pneumococcal Serotypes in Massachusetts’ Children
Background: The direct impact of 13-valent pneumococcal conjugate vaccine (PCV13) on colonization with unique PCV13 serotypes and… Expand
2014
2014
Racial disparities in invasive Streptococcus pneumoniae infections, 1998-2009.
BACKGROUND Before the introduction of 7-valent pneumococcal conjugate vaccine (PCV7), invasive pneumococcal disease (IPD) rates… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2012
Review
2012
Development and clinical evaluation of Prevnar 13, a 13‐valent pneumocococcal CRM197 conjugate vaccine
Pneumococcus is the leading cause of bacterial illness in children worldwide. The development, clinical evaluation, and… Expand
2012
2012
Epidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive Streptococcus pneumoniae isolates in a nationwide surveillance study in Lebanon.
Invasive pneumococcal disease (IPD) associated with Streptococcus pneumonia is a major public health problem worldwide for all… Expand
2011
2011
Análisis de coste-efectividad de la vacunación antineumocócica en España
Objetivo: Analisis de coste-efectividad de la vacunacion antineumococica pediatrica en Espana. Metodos: Se utilizo un modelo… Expand
2002
2002
Pneumococcal Conjugate Vaccine (Prevnar™1; PNCRM7)
SummaryAbstractPNCRM7 (Prevnar™1) is a pneumococcal vaccine containing seven capsular polysaccharide antigens from the bacterium… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE